Upal Roy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2550395/publications.pdf

Version: 2024-02-01

32	1,130	17 h-index	30
papers	citations		g-index
32	32	32	1680 citing authors
all docs	docs citations	times ranked	

#	Article	IF	Citations
1	Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection. Nanomedicine, 2022, 17, 959-978.	3.3	5
2	Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. AIDS Research and Human Retroviruses, 2021, 37, 807-820.	1.1	1
3	The Increase of HIV-1 Infection, Neurocognitive Impairment, and Type 2 Diabetes in The Rio Grande Valley. Current HIV Research, 2020, 17, 377-387.	0.5	2
4	Increased Plasma Levels of the TH2 chemokine CCL18 associated with low CD4+ T cell counts in HIV-1-infected Patients with a Suppressed Viral Load. Scientific Reports, 2019, 9, 5963.	3.3	8
5	The Membrane-Active Phytopeptide Cycloviolacin O2 Simultaneously Targets HIV-1-infected Cells and Infectious Viral Particles to Potentiate the Efficacy of Antiretroviral Drugs. Medicines (Basel,) Tj ETQq1 1 0.78431	.4 ngBT /O	ve ils ck 10 Tf
6	Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain. Scientific Reports, 2018, 8, 1603.	3.3	72
7	Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Scientific Reports, 2016, 6, 25309.	3.3	92
8	Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue. International Journal of Nanomedicine, 2015, 10, 5819.	6.7	25
9	DJ1 expression downregulates in neuroblastoma cells (SK-N-MC) chronically exposed to HIV-1 and cocaine. Frontiers in Microbiology, 2015, 6, 749.	3.5	6
10	Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections. Frontiers in Microbiology, 2015, 6, 948.	3.5	15
11	The potential of HIV-1 nanotherapeutics: from <i>in vitro</i> studies to clinical trials. Nanomedicine, 2015, 10, 3597-3609.	3.3	43
12	HIV Infection and Adipose Tissue Resident Stem Cells: Their Involvement in Pathology and Treatment. Stem Cells and Cancer Stem Cells, 2015, , 21-34.	0.1	0
13	Immunoneuropathogenesis of HIV-1 clades B and C: Role of redox expression and thiol modification. Free Radical Biology and Medicine, 2014, 69, 136-144.	2.9	19
14	Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2013, 57, 3110-3120.	3.2	70
15	Cycloviolacin O2 (CyO2) suppresses productive infection and augments the antiviral efficacy of nelfinavir in HIVâ€1 infected monocytic cells. Biopolymers, 2013, 100, 471-479.	2.4	26
16	Specific Increase in MDR1 Mediated Drug-Efflux in Human Brain Endothelial Cells following Co-Exposure to HIV-1 and Saquinavir. PLoS ONE, 2013, 8, e75374.	2.5	17
17	Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. Aids, 2012, 26, 2135-2144.	2.2	121
18	Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. International Journal of Nanomedicine, 2012, 7, 2373.	6.7	48

#	Article	IF	CITATIONS
19	Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1–Infected Human Peripheral Blood Lymphocyte–Reconstituted Mice. Journal of Infectious Diseases, 2012, 206, 1577-1588.	4.0	62
20	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. International Journal of Nanomedicine, 2011, 6, 3393.	6.7	37
21	Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. Journal of Controlled Release, 2011, 150, 204-211.	9.9	107
22	Mesenchymal stem cell derived hematopoietic cells are permissive to HIV-1 infection. Retrovirology, 2011, 8, 3.	2.0	23
23	UPLC–MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2332-2338.	2.3	33
24	Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs. Journal of Visualized Experiments, 2010, , .	0.3	17
25	Montelukast Is a Potent and Durable Inhibitor of Multidrug Resistance Protein 2-Mediated Efflux of Taxol and Saquinavir. Biological and Pharmaceutical Bulletin, 2009, 32, 2002-2009.	1.4	19
26	Upregulation of HTLVâ€1 and HTLVâ€2 expression by HIVâ€1 in vitro. Journal of Medical Virology, 2008, 80, 494-500.	5.0	7
27	Molecular and phylogenetic analysis of a novel family of fibrinogen-related proteins from mosquito Aedes albopictus cell line. Computational Biology and Chemistry, 2008, 32, 382-386.	2.3	9
28	MRP (ABCC) Transporters-Mediated Efflux of Anti-HIV Drugs, Saquinavir and Zidovudine, from Human Endothelial Cells. Experimental Biology and Medicine, 2008, 233, 1149-1160.	2.4	68
29	Partial genomic organization of ribosomal protein S7 gene from malaria vector Anopheles stephensi. Insect Science, 2007, 14, 101-106.	3.0	1
30	Biodiversity of organotin resistant Pseudomonas from west coast of India. Ecotoxicology, 2007, 16, 253-261.	2.4	14
31	Antimicrobial activity of marine bacteria associated with sponges from the waters off the coast of South East India. Microbiological Research, 2006, 161, 252-262.	5.3	131
32	Microbial transformation of tributyltin chloride byPseudomonas aeruginosa strain USS25 NCIM-5224. Applied Organometallic Chemistry, 2006, 20, 5-11.	3.5	14